Grid Therapeutics is an emerging clinical stage biotechnology company located in Durham, North Carolina. We have made a commitment to our patients and families to develop better and safer therapeutic antibodies for cancer. Grid has a unique and innovative platform to discover human-derived antibodies against novel tumor-specific targets, and can rapidly translate these findings into clinical practice. The Management Team was assembled to rapidly advance these assets to the clinic and have the skillsets and experience to deliver a unique portfolio in the immune-oncology space. The Board of Directors has a deep understanding of the current oncology landscape and is poised to support the Management Team deliver an efficient and impactful development plan. The Advisors and Consultants give context and insight to a wide range of topics such as clinical practice, groundbreaking laboratory techniques, manufacturing, and corporate governance.
Edward Patz is a co-founder and CEO of Grid Therapeutics. For over 25 years, Dr. Patz has been a clinical radiologist and led a basic science laboratory at Duke University Medical Center focused on lung cancer biology and early cancer detection.
Dr. Patz is a member of the Fleischner Society, the International Association for the Study of Lung Cancer, and the Society of Thoracic Radiology. He holds a BS in physics from Duke University, was a researcher in High Energy Physics at Harvard University and received his MD at the University of Maryland. He is currently the James and Alice Chen Professor of Radiology, Professor in Pharmacology and Cancer Biology, and Professor in Pathology at Duke. Dr. Patz previously served on the faculty at Brigham and Women’s Hospital, Harvard Medical School, and the Dana-Farber Cancer Institute.
Scott Lyman is the Chief Business Officer at Grid. Mr. Lyman brings nearly 20 years of program management, finance, corporate strategy, and business development expertise to this role. Prior to joining Grid, Mr. Lyman held a diverse range of roles at Amgen, Valeant, Salix, BioCryst, GlaxoSmithKline, and Becton Dickinson.
Mr. Lyman earned a BS in Chemical Engineering from Iowa State University, an MS in Chemical Engineering from the University of Colorado at Boulder, and an MBA from the University of North Carolina at Chapel Hill.
Thomas L. Patz is the Chief Operating Officer of Grid Therapeutics. For over 20 years prior to joining Grid, Mr. Patz served as Executive Vice President, Strategic Initiatives, and General Counsel of MICROS Systems, Inc., a publicly traded software company. During his tenure at MICROS, Mr. Patz was instrumental in architecting over 30 transactions, including the sale of MICROS to Oracle Corporation in 2014 for $5.3 Billion.
Mr. Patz holds an AB degree from Brown University and a Juris Doctorate from the University of Virginia School of Law.